UNCY - Unicycive Therapeutics Inc
IEX Last Trade
0.3317
-0.011 -3.346%
Share volume: 1,183,547
Last Updated: Fri 30 Aug 2024 09:59:25 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.34
-0.01
-3.24%
Fundamental analysis
31%
Profitability
33%
Dept financing
22%
Liquidity
33%
Performance
30%
Performance
5 Days
-10.63%
1 Month
-19.55%
3 Months
-59.63%
6 Months
-76.04%
1 Year
-55.56%
2 Year
-53.08%
Key data
Stock price
$0.33
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.20 - $1.82
52 WEEK CHANGE
-$0.58
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website: unicycive.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: unicycive.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
unicycive therapeutics is passionate about treating kidney diseases with significant unmet medical needs.
Recent news